Nasdaq exas.

EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...Shares of Exact Sciences ( EXAS 4.73%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ...In the latest trading session, Exact Sciences (EXAS) closed at $66.26, marking a -1.27% move from the previous day. This move lagged the S&P 500's daily gain of 0.57%. Elsewhere, the Dow gained 0. ...2 Nov 2023 ... ... Nasdaq MarketSIte · Trust Center · Newsletters · Chrome Extension · Privacy Policy · Cookies · Legal; Cookies Settings. © 2023, Nasdaq, Inc. All ...Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 67.03 +3.03 (+4.73%) At close: 04:00PM EST 67.03 0.00 (0.00%) After hours: 04:03PM EST 1d 5d

Shares of EXAS stock opened at $67.03 on Monday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.13 and a current ratio of 2.41. The firm has a market cap of $12.12 billion, a ...

Dec 1, 2023 · On November 30, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $64.00 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -4.51%, and its shares gained 38. ... Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis.

Thank you for joining us for Exact Sciences third quarter 2023 conference call. On the call today are Kevin Conroy, the company’s Chairman and CEO, and Jeff Elliott, our Chief Financial Officer ...Find the latest Institutional Holdings data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Thank you for joining us for Exact Sciences third quarter 2023 conference call. On the call today are Kevin Conroy, the company’s Chairman and CEO, and Jeff Elliott, our Chief Financial Officer ...Fintel reports that on October 10, 2023, Piper Sandler upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Neutral to Overweight. As of October 5, 2023, the average one-year price target ...Exact Sciences (NASDAQ:EXAS) is a leading international company specialized in advanced cancer diagnostics. ... To EXAS's credit, this debt issuance has been opportunistic CV offerings, at ...

MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020.

Exact Sciences Corporation (NASDAQ:EXAS) is an extremely timely and compelling short, with an imminent catalyst that we believe will cause shares to plummet as much as 75% in the near future. EXAS ...

"Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ...The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st...Find the latest Earnings Report Date for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ...

Nov 27, 2023 · Exact Sciences Corp. reported an EPS of $0 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went down -1.669%. Which hedge fund is a major shareholder of Exact Sciences Corp.? Turning to the calls side of the option chain, the call contract at the $60.00 strike price has a current bid of $4.20. If an investor was to purchase shares of EXAS stock at the current price ...Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ...Exact Sciences Corp (NASDAQ:EXAS) Exact Sciences Corp. 65.04. Delayed Data. As of Nov 29. +0.09 / +0.14%. Today’s Change. 40.73. Today ||| 52-Week Range.Exact Sciences Corporation EXAS is set to report second-quarter 2022 results on Aug 2, after the closing bell. In the last reported quarter, the company reported a net loss of $1.04, which was ...

Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 64.83 -0.23 (-0.35%) As of 12:06PM EST. Market …Web

The latest price target for Exact Sciences ( NASDAQ: EXAS) was reported by Goldman Sachs on Friday, November 3, 2023. The analyst firm set a price target for 90.00 expecting EXAS to rise to within ...View Our Latest Research Report on EXAS. Exact Sciences Price Performance. Shares of NASDAQ EXAS opened at $67.29 on Tuesday. The stock has a market capitalization of $12.17 billion, a price-to ...Nov 2, 2023 · Thank you for joining us for Exact Sciences third quarter 2023 conference call. On the call today are Kevin Conroy, the company’s Chairman and CEO, and Jeff Elliott, our Chief Financial Officer ... About · Highlight. A leading provider of cancer screening and diagnostic tests · Exchange. NASDAQ · Listing Date. 01/30/2001 · Established Date. 02/10/1995.Dec 2, 2023 · Spyglass Capital Management LLC decreased its holdings in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 36.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 661,930 shares of the medical research company's stock after selling 379,516 shares during the quarter. Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis.11/02/2023 Exact Sciences, a large Cathie Wood holding, came in hot with double-digit sales growth. But EXAS stock reversed lower. 11/02/2023 Exact Sciences, a large Cathie Wood holding, came in ...Exact Sciences (EXAS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures ...One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -16.81%, and its shares gained 127.30% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...

Exact Sciences Co. (NASDAQ:EXAS – Free Report) – Analysts at Leerink Partnrs reduced their Q2 2025 EPS estimates for Exact Sciences in a research report issued to clients and investors on ...

Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt Oct 04. Price target increased by 7.0% to US$109 Sep 19. Exact Sciences Corporation (NasdaqCM:EXAS) agreed to acquire Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A). Sep 13. Executive VP & CFO notifies of intention to sell stock

Exact Sciences (NASDAQ: EXAS) and Guardant Health make diagnostic tests to help screen for cancer. The two healthcare stocks have similar price-to-sales (P/S) ratios, and over the past five years ...Exact Sciences (EXAS) Stock Price, News & Info | The Motley Fool Exact Sciences (NASDAQ: EXAS) $65.99 (0.9%) $0.61 Price as of November 24, 2023, 1:00 p.m. ET …WebFintel reports that on May 10, 2023, B of A Securities maintained coverage of Exact Sciences (NASDAQ:EXAS) with a Buy recommendation.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24 ...Exact Sciences Company Info. EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non ...Exact Sciences Corporation EXAS is set to report second-quarter 2022 results on Aug 2, after the closing bell. In the last reported quarter, the company reported a net loss of $1.04, which was ...Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt Oct 04. Price target increased by 7.0% to US$109 Sep 19. Exact Sciences Corporation (NasdaqCM:EXAS) agreed to acquire Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A). Sep 13. Executive VP & CFO notifies of intention to sell stockExact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2023 financial results after ...Nov 20, 2023 · Kevin Conroy. https://www.exactsciences.com. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Nov 23, 2023 · EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ... Exact Sciences Corporation EXAS is set to report second-quarter 2022 results on Aug 2, after the closing bell. In the last reported quarter, the company reported a net loss of $1.04, which was ...

Nasdaq 14,305.03 +78.81(+0.55%) Russell 2000 1,859.47 +50.45(+2.79%) Crude Oil 74.22 -1.74(-2.29%) Gold 2,089.80 +32.60(+1.58%) Advertisement Exact Sciences Corporation …WebEXACT SCIENCES CORP ( EXAS) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...This year, Exact Sciences (NASDAQ: EXAS) expects its revenue will total just under $2.1 billion. That means that in just five years, its top line will have grown by an incredible 683%.Board. Exact Sciences to participate in November investor conferences. November 01 2023 - 06:00AM. PR Newswire (US) MADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ...Instagram:https://instagram. stock agcopsggamehound labs stockwhat is the price of a gold bar Oct 9, 2023 · MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its ... Dec 4, 2023 · Frontier Capital Management Co. LLC decreased its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 29.1% during the 2nd quarter, according to its most recent disclosure ... paragon 28why nvda stock down The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted).As of today (2023-11-13), Exact Sciences's share price is $59.44.Exact Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.59.Therefore, Exact Sciences's … current home interest rates mn 1. Exact Sciences. Exact Sciences' goal is to eradicate cancer. Perhaps that's too optimistic, but the company could play a role in reducing cancer deaths through its diagnostic solutions.EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission. Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.